FDA panel votes 3-14 that Abbott (ABT) has not found right Humira dose
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
FDA panel votes 3-14 that Abbott (NYSE: ABT) has not found right Humira dose.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Abbott Announces CE Mark for i-STAT Alinity, a Pioneering, Handheld Blood Testing Platform
- Merck's (MRK) sBLA for KEYTRUDA Accepted by U.S. FDA in r/r CHL
- Ignyta (RXDX) Announces Encouraging RXDX-105 Phase 1/1b Data; ORR of 56% Noted
Create E-mail Alert Related CategoriesFDA, General News
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!